The use of stem cells now makes it possible for us to cultivate so-called organoids, such as tiny versions of a liver, heart or small intestine, in the lab. These micro-organs can then be connected to a microchip that simulates the body’s biological processes. This “organ-on-a-chip” technology opens the door to previously undreamed-of research possibilities.
The first drug fully generated by artificial intelligence entered clinical trials with human patients this week. Insilico Medicine, a Hong Kong-based biotech startup with more than $400 million in funding, created the drug, INS018_055, as a treatment for idiopathic pulmonary fibrosis, a chronic disease that causes scarring in the lungs.